In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Ahmed, Nahid H ^a   Baba, Kamaldeen ^a,b   Clay, Cornelis ^a   Lekalakala, Ruth ^a,b   Hoosen, Anwar A ^a,b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

Acinetobacter baumannii complex; Carbapenems; Tigecycline

Indexed keywords

ACINETOBACTER BAUMANNII;

CARBAPENEM DERIVATIVE; DRUG DERIVATIVE; MINOCYCLINE; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFECT; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; SOUTH AFRICA;

ACINETOBACTER BAUMANNII; ADULT; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; SOUTH AFRICA;

EID: 84860369520     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-215     Document Type: Article

References (19)

1. Tigecycline-how powerful is it in the fight against antibiotic-resistant bacteria? V Seputiene, J Povilonis, J Armalyte, K Suziedelis, A Pavilonis, E Suziedeliene, Medicina (Kaunas) 2010 46 4 240 8
2. European Medicines Agency Tygacil, tigecycline http://www.ema.europa.eu/ ema/index.jsp?
3. Activity of tigecycline against clinical isolates ofStaphylococcus aureusand extended-spectrum lactamase-producingEscherichia coliin Granada, Spain. A Sorlozano, J Gutierrez, A Salmeron, JD Luna, F Martinez-Checa, J Roman, G Piedrola, Int J Antimicrob Agents 2006 28 6 532 6 10.1016/j.ijantimicag.2006. 07.010 17045785 (Pubitemid 44779174)
4. Acinetobacter baumannii: Emergence of a Successful Pathogen. AY Peleg, H Seifert, DL Paterson, Clin Microbiol Rev 2008 21 3 538 82 10.1128/CMR.00058-07 18625687
5. Outbreak of carbapenem-resistantAcinetobacter baumanniicarrying the carbapenemase OXA-23 in a German university medical centre. A Kohlenberg, S Brmmer, PG Higgins, D Sohr, BC Piening, C de Grahl, E Halle, H Ruden, H Seifert, J Med Microbiol 2009 58 11 1499 507 10.1099/jmm.0.012302-0 19589905
6. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. DE Karageorgopoulos, T Kelesidis, I Kelesidis, ME Falagas, J Antimicrob Chemother 2008 62 1 45 55 10.1093/jac/dkn165 18436554 (Pubitemid 351865873)
7. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. Z Chen, J Wu, Y Zhang, J Wei, X Leng, J Bi, R Li, L Yan, Z Quan, X Chen, Y Yu, Z Wu, D Liu, X Ma, R Maroko, A Cooper, BMC Infect Dis 2010 21 10 217
8. In-vitro activity of tigecycline against clinical isolates ofAcinetobacter baumanniiin Taiwan. JW Liu, LS Wang, YJ Cheng, GJ Hsu, PL Lu, YC Liu, CM Chen, CM Lee, W Sun, TN Jang, PC Chiang, YC Chuang, HC Lin, ZY Shi, HC Kung, CH Huang, SM Tsao, CT Lu, CH Liao, PR Hsueh, Int J Antimicrob Agents 2008 32 Suppl 3 188 91
9. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. C Bergallo, A Jasovich, O Teglia, ME Oliva, A Lentnek, L de Wouters, JC Zlocowski, G Dukart, A Cooper, R Mallick, 308 Study Group, Diagn Microbiol Infect Dis 2009 63 1 52 61 10.1016/j.diagmicrobio.2008. 09.001 18990531
10. Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia. ML Townsend, MW Pound, RH Drew, Infect Drug Resist 2011 4 77 86 21694911
11. Tigecycline: a glycylcycline antimicrobial agent. TL Doan, HB Fung, D Mehta, PF Riska, Clin Ther 2006 28 8 1079 106 10.1016/j.clinthera.2006.08.011 16982286 (Pubitemid 44376809)
12. Efficacy and safety of tigecycline: a systematic review and meta-analysis. D Yahav, A Lador, M Paul, L Leibovici, J Antimicrob Chemother 2011 66 9 1963 71 10.1093/jac/dkr242 21685488
13. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods. CH Liao, HC Kung, GJ Hsu, PL Lu, YC Liu, CM Chen, CM Lee, W Sun, TN Jang, PC Chiang, YJ Cheng, HC Lin, ZY Shi, LS Wang, YC Chuang, SM Tsao, CT Lu, JW Liu, CH Huang, PR Hsueh, Int J Antimicrob Agents 2008 32 Suppl 3 192 6 18571381
14. Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistantAcinetobacter baumanniithroughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. DJ Hoban, SK Bouchillon, MJ Dowzicky, Journal of Diagnostic Microbiology and Infectious Disease 2007 57 4 423 8 10.1016/j.diagmicrobio.2006. 10.013 (Pubitemid 46498663)
15. Evaluation of tigecycline activity in clinical isolates among Indian medical centers. A Manoharan, S Chatterjee, S Madhan, D Mathai, Indian Journal of Pathology and Microbiology 2010 53 4 734 7 10.4103/0377-4929.72061
16. New information about the polymyxin/colistin class of antibiotics. J Molina, E Cordero, J Pachn, Expert Opin Pharmacother 2009 10 17 2811 28 10.1517/14656560903334185 19929704
17. Antimicrobial treatment and clinical outcomes of carbapenem- resistantAcinetobacter baumanniiventilator-associated pneumonia. JD Chan, JA Graves, TH Dellit, Journal of Intensive Care Medicine 2010 25 6 343 8 10.1177/0885066610377975 20837632
18. Laboratory-based evaluation of the colorimetric VITEK-2 Compact system for species identification and of the Advanced Expert System for detection of antimicrobial resistances: VITEK-2 Compact system identification and antimicrobial susceptibility testing. I Nakasone, T Kinjo, N Yamane, K Kisanuki, CM Shiohira, Diagn Microbiol Infect Dis 2007 58 2 191 8 10.1016/j.diagmicrobio. 2006.12.008 17300904 (Pubitemid 46856805)
19. Clinical and Laboratory Standards Institute, Performance standard for antimicrobial susceptibility testing. Twentieth informational supplement. Document M100-S20 CLSI, Wayne, PA 2010